Search results for "COVID-19"


 
Results 61 - 70 of about 464 for "COVID-19".
Sort by: Relevance | Newest | Oldest

COVID-19 and primary care

This issue also covers personal protective equipment and retirement planning.
https://immattersacp.org/archives/2020/07/covid-19-and-primary-care.htm
1 Jul 2020

Fighting COVID-19 vaccine fallacies with facts

This issue addressed COVID-19 vaccination and integrating oral health into primary care.
https://immattersacp.org/archives/2021/11/fighting-covid-19-vaccine-fallacies-with-facts.htm
1 Nov 2021

MKSAP Quiz: Routine visit for a patient with chronic kidney disease

A 45-year-old man is evaluated during a routine visit in September. He has advanced chronic kidney disease due to IgA nephropathy. After his vaccination history is evaluated, what is the most appropriate additional vaccine to administer at this visit?
https://immattersacp.org/weekly/archives/2023/07/18/3.htm
18 Jul 2023

CBT improved severe fatigue after COVID-19, Dutch trial finds

After randomization, patients with severe fatigue three to 12 months after COVID-19 infection benefited from cognitive behavioral therapy (CBT) compared to usual care.
https://immattersacp.org/weekly/archives/2023/05/16/2.htm
16 May 2023

ACP's commitment to address misinformation and disinformation

The College vigorously supports the use of science and scientific expertise, based on the best available evidence, and remains concerned about the spread of both disinformation and misinformation on social media, public news channels, and other digital channels.
https://immattersacp.org/weekly/archives/2023/02/14/5.htm
14 Feb 2023

Testing offers hope, no panacea for COVID-19 control

A Q&A offers expert advice on the latest information about testing for COVID-19 from Elisa I. Choi, MD, FACP, Governor for ACP's Massachusetts Chapter and a fellow of the Infectious Diseases Society of America.
https://immattersacp.org/archives/2020/06/testing-offers-hope-no-panacea-for-covid-19-control.htm
1 Jun 2020

Nirmatrelvir/ritonavir rarely leads to rebound, doesn't help average-risk patients, studies find

A retrospective analysis found that symptom rebound occurred in less than 1% of high-risk COVID-19 patients treated with nirmatrelvir/ritonavir, while the manufacturer reported that the drug didn't show significant benefit in average-risk patients.
https://immattersacp.org/weekly/archives/2022/06/21/2.htm
21 Jun 2022

Get with the latest ARDS guideline

Experts tasked with updating guidelines on acute respiratory distress syndrome (ARDS) found a lot of new data to incorporate.
https://immattersacp.org/archives/2024/03/get-with-the-latest-ards-guideline.htm
1 Mar 2024

IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir

The Infectious Diseases Society of America (IDSA) listed six steps to help clinicians prescribe the COVID-19 medication while minimizing interaction risks. Other recent research looked at neuropsychiatric conditions after COVID-19 and hospital profits during the pandemic.
https://immattersacp.org/weekly/archives/2022/05/17/2.htm
17 May 2022

10 tips for well-being amid COVID-19

The global pandemic has professional and personal consequences for physicians, so experts offer their advice on coping during COVID-19.
https://immattersacp.org/archives/2020/07/10-tips-for-well-being-amid-covid-19.htm
1 Jul 2020

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next